制药、生物科技和生命科学行业A股上市公司E维度与评级分析：基于2024年度数据-ESG-金融界

Core Viewpoint - The implementation of ESG principles has become a mandatory requirement for companies in the pharmaceutical, biotechnology, and life sciences sectors in China, especially in the context of achieving carbon neutrality and high-quality development goals [1][23]. Group 1: ESG Reporting and Ratings - As of May 5, 2025, 161 companies in the A-share pharmaceutical, biotechnology, and life sciences sectors have actively disclosed their 2024 ESG reports, indicating a growing trend in ESG practices [2]. - The overall ESG practice level in the pharmaceutical, biotechnology, and life sciences sectors is relatively good, with most companies rated at the BBB level, reflecting a positive distribution of ratings [2][23]. - The clarity of environmental management goals is positively correlated with ESG ratings, with 100% of AA and A-rated companies having clear environmental management goals [5][11]. Group 2: Energy Efficiency and Environmental Policies - Companies that prioritize ESG initiatives are increasingly implementing comprehensive energy-saving and renewable energy policies, which are positively correlated with higher ESG ratings [7][8]. - The effectiveness of energy-saving and emission reduction measures is directly proportional to ESG ratings, with higher-rated companies showing better implementation results [19]. Group 3: Environmental Management Certifications - The proportion of companies with ISO 14001 environmental management system certification increases with higher ESG ratings, indicating a correlation between certification and ESG performance [10][11]. - The relationship between green factory certification and ESG ratings is less clear, as many companies with lower ratings have not obtained such certifications, suggesting a need for improvement in this area [13]. Group 4: Environmental Information Disclosure - The quality of environmental information disclosure is crucial for ESG ratings, with companies that provide comprehensive and high-quality disclosures achieving better ratings [15][23]. - Companies with low environmental disclosure quality tend to have lower ESG ratings, highlighting the importance of transparency in environmental performance [15]. Group 5: Biodiversity and Environmental Investment - The emphasis on biodiversity protection is positively correlated with ESG ratings, with higher-rated companies showing a greater commitment to biodiversity initiatives [21][22]. - Environmental investment levels do not show a strong correlation with ESG ratings, indicating that many companies in the sector have low investment in environmental protection [17][23].